Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medication overuse headache.

Mark Obermann1, Thorsten Bartsch, Zaza Katsarava

  • 1Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany. mark.obermann@uni-essen.de

Expert Opinion on Drug Safety
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic tests and headache misdiagnoses in individuals with resistant and refractory migraine - data from the REFINE study.

Cephalalgia : an international journal of headache·2026
Same author

Over 600 million people aged 18-65 will have headache tomorrow: global 1-day prevalence and recall bias from a meta-analysis of individual participant data (N = 38,512) from the general populations of 15 countries.

The journal of headache and pain·2026
Same author

MIDAS and HIT-6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study.

European journal of neurology·2026
Same author

Amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease: from pathophysiology to individualized risk assessment.

Alzheimer's research & therapy·2026
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

The prevalence of headache disorders among children and adolescents in Georgia: a cross-sectional schools-based study.

The journal of headache and pain·2025
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Medication overuse headache (MOH), a growing condition affecting 1% globally, is triggered by frequent use of pain relievers. Effective treatment involves stopping the overused medication.

Area of Science:

  • Neurology
  • Pharmacology
  • Public Health

Background:

  • Medication overuse headache (MOH) is the third most common headache disorder.
  • Its prevalence affects approximately 1% of the global population and is increasing.
  • MOH can affect all age groups, including children.

Purpose of the Study:

  • To present updated data on clinical features of MOH.
  • To provide new information on critical monthly dosages and intake frequencies for headache medications.
  • To discuss withdrawal therapy as the primary treatment and analyze relapse rates.

Main Methods:

  • Review of current literature and prospective studies on MOH.
  • Analysis of clinical features, effective dosages, and intake frequencies of antiheadache drugs.

Related Experiment Videos

  • Evaluation of withdrawal therapy outcomes, including relapse rates and predictors.

    • Main Results:

    • All classes of antiheadache drugs, including triptans, analgesics, ergots, opioids, and combination medications, can induce MOH.
    • New data on critical monthly dosages and intake frequencies are now available.
    • Consequent withdrawal therapy is the only effective treatment approach.

    Conclusions:

    • Medication overuse headache is a significant and growing public health concern.
    • Understanding critical intake thresholds is crucial for prevention and management.
    • Withdrawal therapy is effective, but relapse rates and predictors require further study.